Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib in Moderate to Severe Hidradenitis Suppurativa (STOP-HS LTE)
NCT06212999Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, double-blind trial of povorcitinib in hidradenitis suppurativa (HS) (3 cohorts), sponsored by Incyte. Primary endpoint: Proportion of participants with Treatment-Emergent Adverse Events at 56 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06212999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212999.